Search Results - "Hureaux, J."

Anti‐PD1‐induced psoriasis: a study of 21 patients by Bonigen, J., Raynaud‐Donzel, C., Hureaux, J., Kramkimel, N., Blom, A., Jeudy, G., Breton, A.‐L., Hubiche, T., Bedane, C., Legoupil, D., Pham‐Ledard, A., Charles, J., Pérol, M., Gérard, E., Combemale, P., Bonnet, D., Sigal, M.‐L., Mahé, E.

Get full text

Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01) by Barlesi, F., Gervais, R., Lena, H., Hureaux, J., Berard, H., Paillotin, D., Bota, S., Monnet, I., Chajara, A., Robinet, G.

“…Brain metastases (BM) occur in up to 40% of non-small-cell lung cancer (NSCLC) patients. This trial assessed the safety and efficacy of pemetrexed–cisplatin in…”
Get full text

Corneal graft rejection in a patient treated with nivolumab for primary lung cancer by Le Fournis, S, Gohier, P, Urban, T, Jeanfaivre, T, Hureaux, J

“…Highlights • Immunotherapy is a standard of care for non-operable non-small cell lung cancer. • PD-1 blocking antibodies could promote corneal graft rejection…”
Get full text

Simulation training in pulmonary medicine: Rationale, review of the literature and perspectives by Hureaux, J, Urban, T

“…Training in pulmonary medicine requires the acquisition of a great deal of knowledge, but also technical know-how and interpersonal skills. The prevailing…”
Get more information

A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial by Pujol, J.-L., Greillier, L., Audigier Valette, C., Moro-Sibilot, D., Uwer, L., Hureaux, J., Thiberville, L., Carmier, D., Madelaine, J., Otto, J., Gounant, V., Merle, P., Mourlanette, P., Molinier, O., Renault, P.A., Mazieres, J., Antoine, M., Langlais, A., Morin, F., Souquet, P.-J.

Get full text

Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT‐C33) and specific complementary outpatient module (EORTC OUT‐PATSAT7) by Brédart, A., Anota, A., Young, T., Tomaszewski, K.A., Arraras, J.I., Moura De Albuquerque Melo, H., Schmidt, H., Friend, E., Bergenmar, M., Costantini, A., Vassiliou, V., Hureaux, J., Marchal, F., Tomaszewska, I.M., Chie, W.‐C., Ramage, J., Beaudeau, A., Conroy, T., Bleiker, E., Kulis, D., Bonnetain, F., Aaronson, N.K.

“…Advances in cancer care delivery require revision and further development of questionnaires assessing patients’ perceived quality of care. This study…”
Get full text

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer by Molinier, O., Besse, B., Barlesi, F., Audigier-Valette, C., Friard, S., Monnet, I., Jeannin, G., Mazières, J., Cadranel, J., Hureaux, J., Hilgers, W., Quoix, E., Coudert, B., Moro-Sibilot, D., Fauchon, E., Westeel, V., Brun, P., Langlais, A., Morin, F., Souquet, P.J., Girard, N.

“…Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard…”
Get full text

Inhaled chemotherapy - Part 1: General concept and current technological challenges by Rosière, R, Hureaux, J, Levet, V, Amighi, K, Wauthoz, N

“…Despite severe adverse effects, chemotherapy is still widely used in the treatment of lung tumors, including primary lung tumors and metastases. In order to…”
Get more information

Inhaled chemotherapy - Part 2: Clinical practice and potential applications by Rosière, R, Hureaux, J, Levet, V, Amighi, K, Wauthoz, N

“…Lung tumours have a high incidence and cause many deaths worldwide. Despite progresses in treatment with targeted therapies and immunotherapies, the global…”
Get more information

A bronchial mucous gland adenoma resected by endoscopic procedure by Vergnenègre, C, Hureaux, J, Morvant, B, Urban, T, Jeanfaivre, T

“…Surgical resection is usually performed for the treatment of endobronchial tumors. This case describes the use of endoscopic resection as an initial treatment,…”
Get more information

Can positron emission tomography assessment of response to treatment help to individualize use of erlotinib in non-small cell lung cancer? by Hureaux, J, Couturier, O, Lacœuille, F, Bouchet, F, Chouaïd, C, Saulnier, P, Urban, T

“…Erlotinib can be prescribed in the treatment of locally advanced or metastatic non-small lung cancer cell (NSCLC) after failure of at least one prior…”
Get more information

The adaptation of lipid nanocapsule formulations for blood administration in animals by Hureaux, J., Lagarce, F., Gagnadoux, F., Clavreul, A., Benoit, J.-P., Urban, T.

“…In many cell-culture and animal models, the therapeutic effects of the entrapped drugs in lipid nanocapsules (LNCs) were preserved with low toxicity. These…”
Get full text

Simulation training: a pilot-study on reception of parents in a pediatric intensive care unit by Hureaux, J, Herbreteau, F, Cartier-Chatron, I, Berton, J, Urban, T, Granry, J-C

“…Simulation training is gradually being integrated into the curriculum for caregivers in intensive care units. There are few training programs on communication…”
Get full text

Postmarketing surveillance study on the use of topotecan in small-cell lung cancer. Use of topotecan in a pneumology university department by Hureaux, J, Alizon, C, Urban, T

“…Lung cancer is the leading cause of cancer related death in France and Europe. Small-cell lung carcinoma (SCLC) represents 15-20% of cases. International…”
Get more information

Radiation recall dermatitis with pemetrexed by Hureaux, J., Le Guen, Y., Tuchais, C., Savary, L., Urban, T.

“…Pemetrexed has recently been approved for use in combination with cisplatin as first-line chemotherapy for malignant pleural mesothelioma (MPM). Radiation…”
Get full text

Biological diagnosis of resistance to erlotinib in a malignant pleural effusion by Rieux, C, Boisdron-Celle, M, Morel, A, Fey, L, Urban, T, Hureaux, J

“…The characterization of genetic abnormalities in non-small cell lung cancer (NSCLC) constitutes a theranostic revolution which is leading to rapid progress in…”
Get more information

Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: A GFPC study by Vergnenègre, A, Monnet, I, Chouaïd, C, Hureaux, J, Mazières, J, Quéré, G, Lombard, J.N, Cumin, I, Abdiche, S, Ejnaini, C. Nocent, Bonnabau, H, Decroisette, Ch

“…Abstract Context Erlotinib therapy for non small-cell lung cancer (NSCLC) has mainly been evaluated in randomized trials. Method OBSTAR was a multicenter,…”
Get full text

Cannabis and lung. What we know and everything we don't know yet by Urban, T, Hureaux, J

“…Cannabis use increased sharply from 2010 to 2014 in France. Cannabis is often consumed with tobacco, although the use of marijuana is developing. Tobacco and…”
Get full text

Formation par la simulation : étude-pilote sur l’accueil des parents par une équipe de réanimation pédiatrique by Hureaux, J., Herbreteau, F., Cartier-Chatron, I., Berton, J., Urban, T., Granry, J.-C.

“…Les formations par la simulation sont progressivement intégrées dans les cursus de formation des soignants en réanimation. Il existe peu de formations à la…”
Get full text

1208 Toxicity of systemic administration of blank and paclitaxel-loaded lipid nanocapsules in mice by Lagarce, F, Hureaux, J, Gagnadoux, F, Rousselet, M.C, Moal, V, Benoit, J.P, Urban, T

Get full text